The non-small lung carcinoma market was valued at US$ 8.27 billion in 2023 and is predicted to reach US$ 21.51 billion by the end of 2033, representing an impressive CAGR of 10.03% from 2024 to 2033. Clinical research, development of new treatment options, and prevalence of NSCLC is driving the growth of the market.

Download a sample of this report @ https://www.towardshealthcare.com/download-statistics/5155

Key Takeaways

• By region, North America dominated the non-small lung carcinoma market in 2023, and it is expected to remain dominant during the forecast period.
• By region, Asia Pacific is estimated to grow at the fastest CAGR during the forecast period of 2024-2033.
• By type, the adenocarcinoma segment dominated the market in 2023.
• By type, the squamous cell cancer segment is expected to grow at the fastest CAGR during the forecast period.
• By treatment, the targeted therapy segment dominated the market in 2023.
• By treatment, the immunotherapy segment is expected to grow significantly during the forecast period.
• By distribution channel, the hospital pharmacy segment dominated the non-small lung carcinoma market in 2023.

Industry at a Glance

Non-small cell lung cancer (NSCLC) is the most common type. Around 85% of lung cancer cases are NSCLC. This illness is caused by cancer cells found in lung tissue. While NSCLS progresses more slowly than small-cell lung cancer, it often has spread to other parts of the body by the time it is detected. Timely diagnosis and treatment are of utmost importance. The non-small lung carcinoma market is growing due to the increasing prevalence of lung cancer. The major cause of lung cancer is smoking, and other factors that contribute to NSCLC are air pollution, industrial substances, radiation exposure and tuberculosis. Early detection and treatment of NSCLC are needed.

Laboratory tests, chest X-rays, CT scans, biopsy, sputum cytology, bronchoscopy, thoracoscopy and thoracentesis are some of the diagnoses and tests that need to be done, which drive the growth of the non-small lung carcinoma market. Furthermore, treatment, medications, hospital admission, continuous monitoring, and post-treatment recovery are involved after diagnosis. With time, the cases of NSCLC are increasing; hence, the need for all the tests, treatments, monitoring and other procedures will continue to increase.

Top Companies of the Non-Small Lung Carcinoma Market

• Eli Lilly and Company
• Celgene Corporation
• AstraZeneca
• Bristol-Myers Squibb Company
• Novartis AG
• Sanofi, Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.

Segments Covered in Non-Small Lung Carcinoma Market Report

By Type

• Squamous Cell Carcinoma
• Large Cell Carcinoma
• Adenocarcinoma
• Others

By Treatment Type

• Chemotherapy
• Targeted Therapy
• Immunotherapy

By Distribution Channel

• Hospital Pharmacy
• Drug Store and Retail Pharmacy
• Online Pharmacy

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/non-small-lung-carcinoma-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5155

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare